Patients with colorectal cancer have saved, the national 1.1 targeted medicine brings new choices, expected to be included in medical insurance

Home > Health

Patients with colorectal cancer have saved, the national 1.1 targeted medicine brings new choices, expected to be included in medical insurance

2022-01-15 12:08:02 7 ℃

This is the head of the article

Author: 健识

Normal colon cancer is one of the most common malignant tumors worldwide, and in my country's colorectal cancer is ranked 5th in cancer morbidity and mortality. It is worth noting that nearly half of the colorectal cancer patients are in advanced or due to post-surgical recurrence transfer into advanced disease state, there is a heavy disease burden.

"There are many colorectal cancer patients in my country after the traditional first-line, second-line standard treatment failure, due to various reasons to give up or have been effectively treated." Director of CSCO, Director of the Oriental Hospital of Oriental Hospital, Tongji University, introduced, gratifying my country's first self-developed anti-cancer targeted new drug-Fuquinate, based on better clinical trial data, based on better clinical trial data, breaking the predicament of advanced colorectal cancer, bringing patients New treatment options.

It is undeniable that in the past, metastatic colorectal cancer three-wire therapeutic drug is relatively lacking, and existing treatment means is particularly precious. The Chinese Clinical Tumor Society (CSCO) Guide is updated, and the level I is highly recommended. This shows that CSCO experts strongly recommend this drug for three-line treatment for colorectal cancer.

Many experts in the industry have called for all parties to work together to work together to actively incorporate the anti-cancer innovation drugs of Fuquinateib to the medical insurance catalog. "We already have effective treatment, I hope more colorectal cancer patients will benefit from the dignity of life, so they really feel the love of society and the country."

Normal colon cancer is "rich disease", which is mostly medium and advanced during diagnosis.

Colon cancer, rectal cancer is called colorectal cancer, commonly known as colorectal cancer, is a common malignant tumor commonly used. In recent years, with our lives and economic levels, the residents' diet structure has also occurred, especially in areas with higher economic level. Many people's diet is gradually western, intake high calories, low dietary fiber. There is obesity such as obesity, so that the incidence of colorectal cancer is increased year by year, so it is called "rich disease."

High fat, high protein, low dietary fiber's diet structure, plus exercise is too small, resulting in slow gastrointestinal peristalsis, easy to trigger constipation. In addition, high-fat food will also increase the secretion of the intestinal bile acid, and the intestinal mucosa is stimulated and damaged. The body is in this stimulus and damage, which is easy to induce colorectal cancer.

Compared with other cancers, a major feature of colorectal cancer is that once the diagnosis is mostly a medium and late stage. Since there is no symptom or symptoms of colorectal cancer or symptoms, many people have intestinal cancer, and they don't know early in the early times; and they are mistaken for chronic colitis, acne,



Intestinal obstruction, meat polyps and ulcerative colitis, etc.

If colonal cancer is early, early diagnosis, standard treatment, early colorectal cancer cure rate is more than 90%, so early screening of colorectal cancer must be emphasized. Common methods are colonoscopy. Experts suggest that there are colorectal cancer family history, obesity, smoking, constipation, alcoholism and other people, it is recommended to make an early screening at 40 years old; ordinary people have timely screening at 50 years old and above.

National 1.1 targeted drugs bring new choices, expected to improve the quality of survival of patients

If the colorectal cancer is in a relatively early patient, early diagnosis, early treatment, the effect is ideal; however, for patients with advanced or metastatic colorectal cancer, if it is not active, the prognosis will be relatively poor. At present, the standard treatment of metastatic colorectal cancer is the chemotherapy combined with targeting drug treatment.

For patients with advanced colorectal cancer, effective treatment selection is very limited for second-line chemotherapy failure. After the second-line chemotherapy failed, many patients had a good physical condition and the desire of survival. At this point, whether it is a clinician or a patient, it is desirable to have more "weapons" and treatment.

Fuquinate is a class of targeting vascular cellular growth factor receptor (VEGFR) small molecular inhibitors, which are developed by Huangpu Medicine, with complete intellectual property, and China's first listing 1.1 new drug.

The listing of Fuquinateib fills the gap and provides a large "weapon" for the clinicians, but also brought life in the late colorectal cancer. Fuquinate is a new high-selective small molecule VEGFR1, 2, and 3 inhibitors suitable for chemotherapy that they are currently based on fluorouracil, Orsaliplatin and Irikkkkang, as well as unexpected or unsuitable Vascular endothelial growth factor therapy, anti-glutational growth factor receptor patients with metastatic colorectal cancer patients.

Fuquinate is the three-line treatment of three-line treatment of advanced colorectal cancer in my country, which has a major special support for "major new drug creation" national science and technology, with global independent intellectual property rights. In September 2018, the approval procedures were approved by priority to obtain 1 new drug listing.

Fururoni III Fresco Research is not only reported at the US Oncology (ASCO) annual meeting, but also published in the "Journal of American Medical Association" (JAMA). Fresco Research is a clinical study that mainly assessing the efficacy and safety of patients with carbuquashini in the treatment of metastatic colorectal cancer. It is also the first full text published in China's anti-tumor new drug clinical study on the International Journal of American Medical Association. . Fresco 's research can be on "American Medical Association Magazine" marking international approval in my country' s incology clinical research quality and level. The study shows that furuff is significantly prolonged to 9.3 months, and there is a significant difference in survival, disease control and objective efficiency, etc., good safety. Continue to increase drug availability, patients with advanced colorectal cancer have "love"

Fururonini improved the late colorectal cancer in the past, second-line standard treatment, three-line treatment lacks standard drug optional dilemma. And Fuquinate is a completely developed drug in my country, which makes Chinese doctors more "weapons" than foreign doctors in the treatment option, and has enhanced the national pride of Chinese doctors.

More urgent is, although, Fuquinate has been recommended by the Guide I, but has not been included in the national medical reimbursement system, which is incorporated by Zhuhai into the major illness medical insurance catalog. Shanghai is incorporated into the basic medical insurance catalog, which is undoubtedly can't make more Many patients are reasonably used. In Fresco Research, Fuquashibi is used in the three-line treatment of advanced colorectal cancer and more than 62% of the disease control, which is longeneted and disease control compared to other anti-angiogenesis targeting drugs. The rate is very high, and its poisonous side effect is also more mild, mostly effective controllable. If the drug can be incorporated by the country into the scope of medical insurance, it is believed that it will get a more common application to help more colorectal cancer patients.

The Chinese Clinical Oncology (CSCO) Guide recommended by Fuquinate is used for three-line treatment of patients with advanced colorectal cancer, which provides the basis and reference for the majority of doctors and advanced colorectal cancer patients, and more Doctors from the grassroots hospital and remote areas learned about this country 1.1 excellent innovation drugs. Industry experts have called for the innovative anti-cancer drugs such as burgotinib, such as innovative anticancer drugs such as strong clinical medical needs should be included in the medical insurance catalog, reducing the economic burden of patients, increase the availability of drugs, and make innocent medicines to benefit more colorectal cancer as soon as possible. patient.

This is the end of the article